Breaking News Instant updates and real-time market news.

PCRX

Pacira

$33.30

3.8 (12.88%)

, HRTX

Heron Therapeutics

$26.75

-1.15 (-4.12%)

06:05
04/09/18
04/09
06:05
04/09/18
06:05

Piper reiterates Overweight on Pacira after 'watershed' nerve block approval

FDA approval of Pacira Pharmaceuticals' (PCRX) Exparel as a brachial plexus block "is something of a watershed" in that the agency has never before approved any local or regional anesthetic for a single, specific setting, Piper Jaffray analyst David Amsellem tells investors in a research note. He believes the approval suggests an increasingly aggressive FDA approach towards the opioid crisis. Amsellem points out, however, that feedback from his surgeon survey suggests a "strong degree of enthusiasm" for Heron Therapeutics' (HTRX) HTX-011. However, the feedback also indicates that non-opioid, post-operative pain space is not a zero-sum game, the analyst writes. He believes Exparel can grow "even amid greater competition." Amsellem reiterates an Overweight rating on Pacira with a $44 price target.

PCRX

Pacira

$33.30

3.8 (12.88%)

HRTX

Heron Therapeutics

$26.75

-1.15 (-4.12%)

  • 16

    Apr

  • 08

    May

PCRX Pacira
$33.30

3.8 (12.88%)

04/06/18
WEDB
04/06/18
NO CHANGE
Target $72
WEDB
Outperform
Wedbush says FDA response for Pacira's EXPAREL in nerve block due
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $72 price target on Pacira Pharmaeuticals ahead of the expected PDUFA date for potential expansion of EXPAREL's label to specify nerve block. In a research note to investors, the analyst said she is "hopeful" that EXPAREL could potentially be used to provide improved outcomes in long-acting regional analgesia compared to infusion pumps or opioids. Whether required post-approval or in preparation for future regulatory review, she sees Pacira to continuing to evaluate EXPAREL in different nerve block techniques.
03/21/18
JEFF
03/21/18
NO CHANGE
Target $49
JEFF
Buy
Pacira shares could be positioned for rebound, says Jefferies
Jefferies analyst David Steinberg believes shares of Pacira Pharmaceuticals could be positioned for a rebound after Symphony Health data indicated Exparel posted "well above trend growth" in February. Sales were $24M, up 3.4% from last month and up 12.6% year-over-year, according to Symphony. The data have shown double digit year-over-years gains in four of the past five months, versus just one of nine months prior, Steinberg tells investors in a research note. He believes Pacira is attractively valued at current levels and keeps a Buy rating on the shares with a $49 price target.
03/20/18
GHSC
03/20/18
NO CHANGE
Target $42
GHSC
Buy
Pacira price target lowered to $42 after Heron data at Seaport Global
Seaport Global analyst Corey Davis noted that Heron Therapeutics (HRTX) reported positive results from its two Phase 3 studies of HTX-011 for postoperative pain in bunionectomy and herniorrhaphy. While Heron's HTX-011 data suggest some competition in 2020 for Pacira's (PCRX) Exparel, Davis said dose and volume "present problems" and that Heron "may run into a pricing problem" as well. He reiterates his Buy rating on Pacira shares, though he lowered his price target on the stock to $42 from $50, noting that he has formally removed nerve block revenue for Exparel entirely from his model after the negative FDA AdCom last month.
03/19/18
JEFF
03/19/18
NO CHANGE
Target $30
JEFF
Buy
Heron pain drug 'hits a home run' in Phase III studies, says Jefferies
Jefferies analyst Biren Amin says Heron Therapeutics's (HRTX) HTX-011 "hits a home run" by meeting all primary and key secondary endpoints this morning from Phase III trials in bunionectomy and hernia repair. Safety looked clean in both studies, and HTX-011 produced durable pain reduction up to 72 hours and significant opioid sparing effect and differentiates from generic bupivacaine, Amin tells investors in a research note. The analyst believes HTX-011 should receive a superiority claim versus generic bupivacaine in its label for both bunionectomy and hernia surgery. Amin notes that Pacira's (PCRX) Exparel does not have this claim in its label. He assumes peak sales of $545M for HTX-011 and keeps a Buy rating on Heron with $30 price target.
HRTX Heron Therapeutics
$26.75

-1.15 (-4.12%)

04/05/18
EVER
04/05/18
INITIATION
Target $56
EVER
Outperform
Heron Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Joshua Schimmer started Heron Therapeutics (HRTX) with an Outperform rating and $56 price target. He said that given the marked differentiation versus Pacira's (PCRX) Exparel, peak sales for Heron's HTX-011 could approach $2.5B, while Sustol/Cinvanti could add another $300M at peak. These estimates could drive a valuation potentially approaching $11B, or nearly $175 per share, in a bullish scenario, said Schimmer.
04/05/18
LSCM
04/05/18
NO CHANGE
Target $42
LSCM
Buy
Heron 'ready for liftoff' after secondary offering, says Lake Street
Lake Street analyst Bruce Jackson updated his model for Heron Therapeutics following the recently completed stock offering. In a research note partially titled, "Fuel Tank Filled, Ready For Lift Off," the analyst reiterates a Buy rating on Heron with a $42 price target. New Phase 3 data for HTX-011 demonstrated statistically significant reductions in pain intensity and opioid use through 72 hours post-surgery compared to placebo and the current standard of care, bupivacaine, Jackson writes. He notes that management believes the data support an opioid-sparing labeling claim for HTX-011. This would provide a significant competitive advantage, the analyst contends.
03/20/18
NEED
03/20/18
NO CHANGE
Target $42
NEED
Buy
Heron Therapeutics price target raised to $42 from $30 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $42 after the company's phase 3 trial results for HTX-011 on post-surgical pain management. The analyst says the treatment met all the primary and secondary endpoints while also demonstrating superiority over placebo and bupivacaine in terms of pain relief and opioid consumption. Belanger keeps his Buy rating on Heron Therapeutics, adding that the HTX-011 could be "game changer", with NDA filing coming in the second half of this year.

TODAY'S FREE FLY STORIES

KEG

Key Energy

$8.25

0.02 (0.24%)

06:10
11/20/18
11/20
06:10
11/20/18
06:10
Downgrade
Key Energy rating change  »

Key Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:09
11/20/18
11/20
06:09
11/20/18
06:09
Hot Stocks
Lowe's sees 'positive trends' in FY19 »

Lowe's CEO Marvin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

STXB

Spirit of Texas Bancshares

$19.23

-0.66 (-3.32%)

06:08
11/20/18
11/20
06:08
11/20/18
06:08
Initiation
Spirit of Texas Bancshares initiated  »

Spirit of Texas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:07
11/20/18
11/20
06:07
11/20/18
06:07
Hot Stocks
Lowe's to exit Mexico retail operations, exploring strategic alternatives »

Management has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

STKS

One Group Hospitality

$2.77

-0.18 (-6.10%)

06:06
11/20/18
11/20
06:06
11/20/18
06:06
Initiation
One Group Hospitality initiated  »

One Group Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:04
11/20/18
11/20
06:04
11/20/18
06:04
Earnings
Lowe's sees FY18 adj. EPS $5.08-$5.13, consensus $5.15 »

Sees FY18 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CDNS

Cadence Design

$42.78

-2.98 (-6.51%)

, SNPS

Synopsys

$85.72

-4.37 (-4.85%)

06:04
11/20/18
11/20
06:04
11/20/18
06:04
Initiation
Cadence Design, Synopsys initiated  »

Cadence Design initiated…

CDNS

Cadence Design

$42.78

-2.98 (-6.51%)

SNPS

Synopsys

$85.72

-4.37 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

  • 13

    Dec

  • 12

    Mar

KW

Kennedy Wilson

$18.63

-0.2 (-1.06%)

06:03
11/20/18
11/20
06:03
11/20/18
06:03
Hot Stocks
Kennedy Wilson signs two lease deals in Europe with WeWork and ASOS »

Kennedy Wilson has signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:02
11/20/18
11/20
06:02
11/20/18
06:02
Earnings
Lowe's reports Q3 adj. EPS $1.04, consensus 98c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SNPS

Synopsys

$85.72

-4.37 (-4.85%)

06:02
11/20/18
11/20
06:02
11/20/18
06:02
Initiation
Synopsys initiated  »

Synopsys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 13

    Dec

CYAD

Celyad

$26.97

(0.00%)

06:00
11/20/18
11/20
06:00
11/20/18
06:00
Conference/Events
Celyad management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 22

    Nov

  • 27

    Nov

  • 01

    Dec

  • 03

    Dec

  • 10

    Dec

CSII

Cardiovascular Systems

$28.79

-1.7 (-5.58%)

05:59
11/20/18
11/20
05:59
11/20/18
05:59
Conference/Events
Cardiovascular Systems management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ACAD

Acadia

$18.14

-0.78 (-4.12%)

, KKR

KKR

$21.08

-0.75 (-3.44%)

05:58
11/20/18
11/20
05:58
11/20/18
05:58
Periodicals
KKR still in talks to buy Acadia Healthcare, NY Post reports »

KKR (KKR) is still deep…

ACAD

Acadia

$18.14

-0.78 (-4.12%)

KKR

KKR

$21.08

-0.75 (-3.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGL

Madrigal Pharmaceuticals

$120.49

-8.98 (-6.94%)

05:57
11/20/18
11/20
05:57
11/20/18
05:57
Conference/Events
Madrigal Pharmaceuticals management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MCD

McDonald's

$186.69

-0.96 (-0.51%)

05:54
11/20/18
11/20
05:54
11/20/18
05:54
Conference/Events
McDonald's management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

KEX

Kirby

$74.67

-1.225 (-1.61%)

05:51
11/20/18
11/20
05:51
11/20/18
05:51
Conference/Events
Kirby management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

EFX

Equifax

$101.75

0.84 (0.83%)

05:50
11/20/18
11/20
05:50
11/20/18
05:50
Periodicals
Equifax to cut 33 jobs from Garden City office, NY Post reports »

Equifax is planning to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IOVA

Iovance Biotherapeutics

$8.90

-0.68 (-7.10%)

05:47
11/20/18
11/20
05:47
11/20/18
05:47
Conference/Events
Iovance Biotherapeutics management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

FLWS

1-800-Flowers.com

$12.55

-0.2 (-1.57%)

05:45
11/20/18
11/20
05:45
11/20/18
05:45
Conference/Events
1-800-Flowers.com management to meet with Craig Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

BSX

Boston Scientific

$35.29

-1.93 (-5.19%)

05:45
11/20/18
11/20
05:45
11/20/18
05:45
Conference/Events
Boston Scientific to host investor update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

DHR

Danaher

$101.29

-1.95 (-1.89%)

05:45
11/20/18
11/20
05:45
11/20/18
05:45
Conference/Events
Danaher management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 30

    Nov

  • 13

    Dec

ARRS

Arris

$30.67

0.01 (0.03%)

05:44
11/20/18
11/20
05:44
11/20/18
05:44
Conference/Events
Arris management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 13

    Dec

COO

Cooper Companies

$256.76

-8.32 (-3.14%)

05:43
11/20/18
11/20
05:43
11/20/18
05:43
Recommendations
Cooper Companies analyst commentary  »

Cooper fundamentals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 06

    Dec

AMP

Ameriprise

$125.95

-0.645 (-0.51%)

05:43
11/20/18
11/20
05:43
11/20/18
05:43
Conference/Events
Ameriprise management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

EPAM

Epam Systems

$120.96

-4.25 (-3.39%)

05:39
11/20/18
11/20
05:39
11/20/18
05:39
Initiation
Epam Systems initiated  »

Epam Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.